GSK Expands AI Drug Discovery Deal With Chai Discovery After Its Own Scientists Validate the Models in the Lab
GSK widened its AI drug discovery collaboration with Chai Discovery in October 2026 after its own scientists ran wet-lab tests on Chai's zero-shot protein design models and found binders against every target they tried.
Andromeda Robotics Brings Its Abi Companion Robot to US Senior Care Facilities After $17 Million Raise
Andromeda Robotics raised $17 million to expand its Abi senior-care companion robot into the US market, part of a growing wave of AI robots aimed at easing loneliness and supporting aging-in-place care.
Study Warns AI Is Quietly Reshaping How Insurers Decide — and Deny — Health Claims
A Health Affairs study published October 5 examines the consequences of AI-assisted insurance denial appeals, as insurers increasingly automate both claims denials and the appeals process meant to challenge them.
AI Drug Discovery Deals Top $47 Billion in Just Six Months, Yet No AI-Designed Drug Has Won FDA Approval
AI-based drug discovery licensing deals reached $47.1 billion in the first half of 2026, already surpassing all of 2025's total, even as the industry awaits its first fully FDA-approved AI-discovered drug.
Zealand Pharma Partners With AI Biotech Generate on Next-Generation Weight-Loss Protein Drugs
Zealand Pharma has linked up with AI protein design company Generate Biomedicines to develop multispecific protein therapies for weight loss, extending the Danish company's pipeline of obesity treatments.
OpenAI Acquires Orchestra Bio, Folding Drug-Program AI Agents Into Its Rosalind Life Sciences Suite
OpenAI announced on October 20 that it acquired Orchestra Bio, a startup whose AI agents track drug-development timelines for biopharma teams, folding the technology into its Rosalind life sciences suite already used by Moderna and Novo Nordisk.
Anthropic Buys One-Person Biotech Mithril Medicine, Opens Claude-Run Drug Pipeline With Six Pharma Partners
Anthropic announced on October 27 that it acquired Mithril Medicine, a biotech founded and run by a single scientist, and disclosed six separate pharma collaborations as it moves from selling AI tools to running its own Claude-assisted drug programs.
Suki Raises $90 Million Series E as Its AI Medical Scribe Hits 450 Health System Customers
Suki closed a $90 million Series E led by Healthier Capital, scaling its AI medical-scribe platform to roughly 450 customers and projecting as much as $80 million in 2026 revenue, as ambient-documentation tools become one of the most adopted categories in clinical AI.
Aidoc Raises $150 Million Series E Led by Goldman Sachs to Scale Its Hospital Diagnostic AI
Aidoc closed a $150 million Series E led by Goldman Sachs Alternatives, pushing its total funding past $500 million as the hospital imaging-AI company pivots from single-disease alerts toward a broader clinical foundation model.